Novartis AG (NVS) Stock Analysis & Investment Frameworks
Novartis AG (NVS) stock analysis on Invetso. Review Novartis AG’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Novartis AG Company Overview
- Exchange: New York Stock Exchange
- Sector: Healthcare
- Industry: Drug Manufacturers - General
- Country: CH
Novartis AG Key Financial Metrics
- Market Cap: $292.58B
- Revenue: $54.81B
- P/E Ratio: 20.83
- ROE: 29.64%
- ROIC: 13.38%
- Dividend Yield: 2.92%
About Novartis AG
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
Novartis AG Investment Frameworks
Invetso analyzes Novartis AG (NVS) across the following frameworks:
- Novartis AG 10Y Growth Potential
- Novartis AG Scenario Analysis
- Novartis AG Risks & Opportunities
- Novartis AG Economic Moat
- Novartis AG Business Model
- Novartis AG Management
- Novartis AG SWOT Analysis
- Novartis AG Porter's 5 Forces
- Novartis AG PESTLE Analysis
- Novartis AG ESG Analysis